Drug maker tracks Kids' arthritis treatment experience
NCT ID NCT05754710
Summary
This study monitors the safety and effectiveness of Xeljanz in children with juvenile arthritis during routine medical care in Korea. It follows 10 patients aged 2-18 who are already prescribed Xeljanz for up to 44 weeks. The goal is to collect real-world information about how children respond to this medication in everyday practice.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer
RECRUITINGSeoul, South Korea
Conditions
Explore the condition pages connected to this study.